Tiotropium Bromide
DrugTiotropium bromide 18 micrograms
Other names: Spiriva®
NCT Number: NCT02172495
Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tiotropium bromide 18 micrograms
Other names: Spiriva®
Time frame: Baseline, after 4 weeks
Time frame: Baseline, after 4 weeks
Time frame: Baseline, after 4 weeks
Time frame: Baseline, after 4 weeks
Time frame: Baseline, after 4 weeks
Time frame: 4 weeks
Boehringer Ingelheim
Industry
Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial DetailsNCT07649577
Asthma, Bronchial Diseases
Amman, Jordan
View Trial DetailsNCT06979518
Chronic Disease, Disease Attributes
Cypress, California, United States
View Trial DetailsNCT06367686
Apnea, Chronic Disease
Tønsberg, Norway
View Trial Details